Dr Gutkind is a Professor in the department of Pharmacology and is Associate Director of Basic Science, Moores Cancer Center, he is also Co-Director, Head and Neck Cancer Center, University of California San Diego
Dr. Gutkind is a basic and translational scientist with a passion for exploiting the emerging information on dysregulated signaling circuitries and individual genomic and molecular alterations to develop new precision therapies to prevent and treat cancer. He received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and after his post-doctoral training at the NIMH and NCI, he joined the NIDCR, NIH. He served as the Chief of the Oral and Pharyngeal Cancer Branch, NIDCR, since 1998 until his recent recruitment as Associate Director of Basic Science, Moores Cancer Center, UCSD, in 2015. Dr. Gutkind is a national and international leader in the study of basic signal transduction mechanisms in cancer. He is recognized for his pioneering work revealing the potent oncogenic activity of G proteins and G protein coupled receptors (GPCRs) and by his studies unraveling the molecular mechanisms by which they promote normal and malignant cell growth.
As part of his translation efforts, Dr. Gutkind has led a multi institutional clinical trial establishing the benefits of treating oral cancer patients with mTOR inhibitors, and he is co-leading a new mTOR-targeting chemoprevention medicine trial in oral premalignancy.
He has been the recipient of numerous awards, edited three books, and published over 470 research studies and review articles in some of the most prestigious journals. He has organized multiple national and international meetings and symposia, and he is a member of numerous editorial boards of scientific journals and national and international advisory committees. He has supervised and mentored many junior investigators, who are now playing leadership roles in multiple institutions in the US and abroad.